Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and methods for treatment of hemopigmentation

A hemoglobin and polynucleotide technology, applied in biochemical equipment and methods, other methods of inserting foreign genetic materials, gene therapy, etc., can solve problems such as loss and complicated application

Inactive Publication Date: 2022-03-01
ULTRAGENYX PHARMA INC
View PDF30 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Secondary hemochromatosis is often treated with iron chelators such as deferoxamine or deferasirox, but unfortunately, these therapies can be complex to administer, require an unusual commitment of time from the patient, and / Or associated with adverse effects such as hypotension, GI disturbances, vision and hearing loss, and abnormal liver and kidney function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treatment of hemopigmentation
  • Compositions and methods for treatment of hemopigmentation
  • Compositions and methods for treatment of hemopigmentation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0272] Example 1: Expression of HFE protein in hepatocytes from HFE mRNA.

[0273] This example demonstrates that exogenous HFE protein can be produced in cultured primary human hepatocytes following mRNA transfection using a commercially available delivery agent.

[0274] Primary human hepatocytes (Thermo-Fisher Scientific) were purchased, recovered by freezing, and plated according to the manufacturer's recommended protocol. Lipofectamine MessengerMAX (Thermo-Fisher Scientific) was used to transfect codon-optimized HFE-encoding mRNA (modified to use N1-methyl-pseudouridine ["N1MPU"] or 5-methoxyuridine [" 5MOU”] to replace uridine). The RNA sequence used in this example is shown in SEQ ID NO:67, which includes a 5' cap (providing a single 5'A residue), the 5'UTR of SEQ ID NO:33, the HFE coding sequence of SEQ ID NO:4 (encoding the protein of SEQ ID NO:32) and the 3'UTR of SEQ ID NO:35.

[0275] Twenty-four hours after transfection, cells were lysed in RIPA buffer for subs...

Embodiment 2

[0278] Example 2: Duration of HFE protein expression in hepatocytes from HFE mRNA.

[0279] This example demonstrates the duration of exogenous HFE expression following transfection of HFE mRNA using a commercially available delivery agent.

[0280] Primary human hepatocytes (Thermo-Fisher Scientific) were purchased, recovered by freezing, and plated according to the manufacturer's recommended protocol. Lipofectamine MessengerMAX (Thermo-Fisher Scientific) was used to transfect 500 ng of codon-optimized HFE-encoding mRNA (modified to use N1-methyl-pseudouridine ["N1"] or 5-methoxyuridine ["5MU"] replace uridine). The RNA sequence used in this example is shown in SEQ ID NO:67, which includes a 5' cap (providing a single 5'A residue), the 5'UTR of SEQ ID NO:33, the HFE coding sequence of SEQ ID NO:4 ( encodes the protein of SEQ ID NO:32) and the 3'UTR of SEQ ID NO:35.

[0281] Twenty-four hours after transfection (and every day thereafter), cells were lysed in RIPA buffer for...

Embodiment 3

[0284] Example 3: Expression of hepatic HFE protein and reduction of peripheral iron levels in Hfe knockout mice.

[0285] This example demonstrates that administration of HFE-encoding mRNA encapsulated in lipid nanoparticles can produce hepatic HFE protein expression in a dose-dependent manner in Hfe knockout mice.

[0286] In this example, mRNA (SEQ ID NO:67) capable of encoding human HFE was encapsulated in lipid nanoparticles and administered to Hfe via tail vein injection at 0.3 mg / kg, 1 mg / kg and 3 mg / kg. knockout mice. Approximately 48 hours after dosing, livers were harvested and blood was collected for determination of iron levels.

[0287] After a single dose of HFE-encoding mRNA, dose-dependent HFE protein expression was observed in mouse liver homogenates by anti-HFE immunoblotting ( image 3 ). A subsequent restoration of hepcidin gene expression was observed in treated mice by branched DNA (bDNA) assays at levels similar to wild-type controls ( Figure 4 ). ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application provides a polynucleotide comprising a coding sequence of a functionally active hereditary hemopigmentation protein (HFE) or a functionally active fragment thereof. The invention further provides compositions comprising the polynucleotides and their use in methods of preventing or treating hematopigmentation in a subject.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 852,549, filed May 24, 2019, and U.S. Provisional Application No. 62 / 991,907, filed March 19, 2020, the contents of each of which are hereby incorporated by reference in their entirety. [0003] field of invention [0004] The present invention relates to a nucleic acid molecule encoding a hereditary hemochromatosis protein (HFE) and a composition comprising the nucleic acid molecule for use in the treatment of hemochromatosis. [0005] Background of the invention [0006] Hereditary hemochromatosis (HH), also known as type 1 hemochromatosis or genetic hemochromatosis, is an autosomal recessive disorder caused by a mutant HFE protein (also known as hereditary Hemochromatosis protein). Even with normal dietary intake, mutations in the HFE protein cause increased intestinal iron absorption, resulting in large amounts of iron being deposited in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00C12N15/90C12N5/071C12N15/10
CPCA61K48/005A01K67/0276A01K2217/075A01K2227/105A01K2267/0306C07K14/70539C12P19/34C12N15/113C07K14/4702A61K31/7088A61K38/00C12N2800/22C12N2310/335C12N2310/317C12N2830/50C12N2310/321
Inventor S.C.多尔蒂T.P.黄R.D.卡森J.R.卡塔尔多
Owner ULTRAGENYX PHARMA INC